ARGX Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 25.88% compared to argenx SE's net margin of -64.14%. argenx SE's return on equity of 28.06% beat Evaxion AS's return on equity of --.

argenx SE has a consensus price target of $978.59, signalling upside risk potential of 6.84%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 167.96%. Given that Evaxion AS has higher upside potential than argenx SE, analysts believe Evaxion AS is more attractive than argenx SE.

argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than Evaxion AS quarterly revenues of $37.5K. argenx SE's net income of $245.4M is higher than Evaxion AS's net income of -$4.9M. Notably, argenx SE's price-to-earnings ratio is 46.56x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 19.54x versus 3.55x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Merus NV has a net margin of 25.88% compared to argenx SE's net margin of -786.17%. argenx SE's return on equity of 28.06% beat Merus NV's return on equity of -53.47%.

argenx SE has a consensus price target of $978.59, signalling upside risk potential of 6.84%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.92%. Given that argenx SE has higher upside potential than Merus NV, analysts believe argenx SE is more attractive than Merus NV.

argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than Merus NV quarterly revenues of $12.2M. argenx SE's net income of $245.4M is higher than Merus NV's net income of -$95.5M. Notably, argenx SE's price-to-earnings ratio is 46.56x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 19.54x versus 120.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

ProQR Therapeutics NV has a net margin of 25.88% compared to argenx SE's net margin of -381.88%. argenx SE's return on equity of 28.06% beat ProQR Therapeutics NV's return on equity of -67.34%.

argenx SE has a consensus price target of $978.59, signalling upside risk potential of 6.84%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 341.54%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.

argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. argenx SE's net income of $245.4M is higher than ProQR Therapeutics NV's net income of -$12.9M. Notably, argenx SE's price-to-earnings ratio is 46.56x while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 19.54x versus 12.16x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.

uniQure NV has a net margin of 25.88% compared to argenx SE's net margin of -2175.87%. argenx SE's return on equity of 28.06% beat uniQure NV's return on equity of -382.35%.

argenx SE has a consensus price target of $978.59, signalling upside risk potential of 6.84%. On the other hand uniQure NV has an analysts' consensus of $58.48 which suggests that it could grow by 129.5%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.

argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than uniQure NV quarterly revenues of $3.7M. argenx SE's net income of $245.4M is higher than uniQure NV's net income of -$80.5M. Notably, argenx SE's price-to-earnings ratio is 46.56x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 19.54x versus 87.06x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.